MTEM - Molecular Templates, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Molecular Templates, Inc.

9301 Amberglen Boulevard
Suite 100
Austin, TX 78729
United States

Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Dr. Eric E. PomaCEO, Chief Scientific Officer & Director606.54kN/A1972
Ms. Jason S KimPres & COO444.74kN/A1975
Mr. Adam D. Cutler B.A.Chief Financial OfficerN/AN/A1974
Mr. Kurt ElsterExec. VP of Corp. Devel.N/AN/A1967
Dr. Jack Higgins Ph.D.Exec. VP of Operations & Head of ManufacturingN/AN/A1980
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.

Corporate Governance

Molecular Templates, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.